ADL is a fully human anti-TNF mAb IgG1 approved for ankylosing spondylitis (AS), Crohn’s Disease (CD), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), psoriasis (Ps), rheumatoid arthritis (RA), and urticarial vasculitis (UV). This evidence concerns the gene TNF and psoriatic arthritis.